Skip to main content

COVID and the flu present a clash of viruses

Good afternoon, readers.

It’s that time of year again. Yes, the time of year when public health experts bug you to get your flu shot.

We all know that the flu shot isn’t perfect. Sure, you may still get influenza after getting your yearly jab. Sure, its effectiveness varies wildly from year to year given that the flu virus mutates.

But the pathogen still kills tens of thousands of people every year—one of the main reasons that those trying to downplay the coronavirus risk have compared that virus to influenza.

This year, however, COVID has already claimed more than 200,000 American lives in a far shorter timeline than what we see from the flu. And as we step towards October, flu season will rear its head again as the coronavirus pandemic continues to rage unabated.

That’s a problem on multiple fronts. For one thing, it might be difficult to distinguish who has the flu and who has COVID. Hospitals may continue to see surging cases of both diseases which can drain their resources. And a country eager to just get back to normal may not be willing to avoid close indoor contact during the holiday season.

Read on for the day’s news, and see you again next week.

Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy



from Fortune https://ift.tt/3mPkxH4
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more